Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients

February 11, 2026 updated by: University of Lahore

Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.

Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The observed effects are likely mediated by HCA, which inhibits ATP-citrate lyase, reducing de novo lipogenesis, enhancing glucose utilization, and modulating adipokines and oxidative stress.

Conclusion: Garcinia cambogia rind powder supplementation exerts dose-dependent metabolic benefits in pre-diabetic obese adults, improving anthropometric, glycemic, lipid, hepatic, and renal parameters without adverse effects. It may serve as a complementary intervention alongside lifestyle modification for the management of obesity and pre-diabetes.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan, 54000
        • Sana Noreen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants of both genders were included if they were aged 30-60 years,
  • body mass index (BMI) ≥30 kg/m²,
  • Individuals with HbA1c levels ranging from 5.7% to 10% were selected, .indicating pre-diabetic to diabetic status. Participants were required to have a .body mass index (BMI) of 25 kg/m² or higher

Exclusion Criteria:

  • Participants who were diagnosed with type 1, pregnant or lactating,
  • chronic liver, kidney, or cardiovascular disease,
  • history of hepatotoxicity or gastrointestinal disorders,
  • using weight-loss supplements, steroids, or lipid-lowering drugs, or had a known allergy to Garcinia cambogia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo group
Starch capsule once a day
Dietary supplement: Garcinia cambogia rind powder
Once a day
Dietary supplement: Garcinia cambogia rind powder
Once a day for 12 weeks
Experimental: T1
100mg/day of Garcinia cambogia rind powder
Dietary supplement: Garcinia cambogia rind powder
Once a day
Dietary supplement: Garcinia cambogia rind powder
Once a day for 12 weeks
Experimental: T2
200mg/day of Garcinia cambogia rind powder
Dietary supplement: Garcinia cambogia rind powder
Once a day
Dietary supplement: Garcinia cambogia rind powder
Once a day for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Weight
Time Frame: 12 weeks
12 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
fasting glucose
Time Frame: 12 weeks
12 weeks
Lipid profile
Time Frame: 12 weeks
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2025

Primary Completion (Actual)

November 24, 2025

Study Completion (Actual)

January 1, 2026

Study Registration Dates

First Submitted

February 11, 2026

First Submitted That Met QC Criteria

February 11, 2026

First Posted (Actual)

February 18, 2026

Study Record Updates

Last Update Posted (Actual)

February 18, 2026

Last Update Submitted That Met QC Criteria

February 11, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UOL/IREB/25/12/0053

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lipid Profile

Clinical Trials on Garcinia cambogia rind powder

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe